NCRI 2018 | Highlighting a subset of TNBC for targeted therapy

Adrian Harris, MD, DPhil, from the University of Oxford, Oxford, UK, speaks at the 2018 National Cancer Research Institute (NCRI) Cancer Conference, held in Glasgow, UK, about a challenge associated with the treatment of triple negative breast cancer (TNBC). Prof. Harris highlights a challenge in treating those with residual disease after therapy. An approach to understanding the molecular mechanisms underlying TNBC and thus identify targets in individual patients is discussed as a way forward.